418
EQUINE VETERINARY EDUCATION / AE / AUGUST 2019
Burnett, R.C., Vernau, W., Modiano, J.F., Olver, C.S., Moore, P.F. and Avery, A.C. (2003) Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet. Pathol. 40, 32-41.
Durham, A.C., Pillitteri, C.A., San Myint, M. and Valli, V.E. (2013) Two hundred three cases of equine lymphoma classified according to the World Health Organization (WHO) classification criteria. Vet. Pathol. 50, 86-93.
Gress, V., Wolfesberger, B., Fuchs-Baumgartinger, A., Nedorost, N., Saalmuller, A., Schwendenwein, I., Rutgen, B.C. and Hammer, S.E. (2016) Characterization of the T-cell receptor gamma chain gene rearrangements as an adjunct tool in the diagnosis of T-cell lymphomas in the gastrointestinal tract of cats. Res. Vet. Sci. 107, 261-266.
Keller, S.M., Vernau, W. and Moore, P.F. (2016) Clonality testing in veterinary medicine: a review with diagnostic guidelines. Vet. Pathol. 53, 711-725.
Lana, S.E., Jackson, T.L., Burnett, R.C., Morley, P.S. and Avery, A.C. (2006) Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. J. Vet. Intern. Med. 20, 329-334.
Lane, J.G. (1985) Palatine lymphosarcoma in two horses. Equine Vet. J. 17, 465-467.
Langner, K.F., Joetzke, A.E., Nerschbach, V., Eberle, N., Schuberth, H.- J., Koy, M., Nolte, I. and Betz, D. (2014) Detection of clonal antigen receptor gene rearrangement in dogs with lymphoma by real-time polymerase chain reaction and melting curve analysis. BMC Vet. Res. 10, 1-11.
Lawn, K. (2005) Sudden death due to thoracic lymphoma in a standardbred racing horse. Can. Vet. J. 46, 528-529.
Lester, G.D., MacKay, R.J. and Smith-Meyer, B. (1992) Primary meningeal lymphoma in a horse. J. Am. Vet. Med. Assoc. 201, 1219-1221.
Marques, F.J., Hehenberger, E., Dickinson, R., Wojnarowicz, C. and Lohmann, K. (2012) Respiratory distress due to retropharyngeal and neck swelling in a horse with mediastinal lymphosarcoma. Compend. Contin. Educ. Vet. 34, E5.
McCarthy, P.H. (1990) The triangle of Viborg (Trigonum viborgi) and its anatomical relationships in the normal standing horse. Anat. Histol. Embryol. 19, 303-313.
Meichner, K., Kraszeski, B.H., Durrant, J.R., Grindem, C.B., Breuhaus, B.A., Moore, P.F., Neel, J.A., Linder, K.E., Borst, L.B., Fogle, J.E. and Tarigo, J.L. (2017) Extreme lymphocytosis with myelomonocytic morphology in a horse with diffuse large B-cell lymphoma. Vet. Clin. Pathol. 46, 64-71.
Meyer, J., Delay, J. and Bienzle, D. (2006) Clinical, laboratory, and histopathologic features of equine lymphoma. Vet. Pathol. 43, 914-924.
Regu-Mate®(altrenogest)
Solution 0.22% (2.2 mg/mL) CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
DESCRIPTION: Regu-Mate® (altrenogest) Solution 0.22% contains the active synthetic progestin, altrenogest. The chemical name is 17-allyl-17ß-hydroxyestra- 4,9,11-trien-3-one.
The CAS Registry Number is 850-52-2. The chemical structure is:
Montgomery, J.B., Duckett, W.M. and Bourque, A.C. (2009) Pelvic lymphoma as a cause of urethral compression in a mare. Can. Vet. J. 50, 751-754.
Munoz, A., Riber, C., Trigo, P. and Castejon, F. (2009) Hematopoietic neoplasias in horses: myeloproliferative and lymphoproliferative disorders. J. Equine Sci. 20, 59-72.
Rebhun, W.C. and Del Piero, F. (1998) Ocular lesions in horses with lymphosarcoma: 21 cases (1977-1997). J. Am. Vet. Med. Assoc. 212, 852-854.
Rhind, M. and Dixon, P.M. (1999) T cell-rich B cell lymphosarcoma in the tongue of a horse. Vet. Rec. 145, 554-555.
Sato, H., Fujino, Y., Uchida, K., Ohno, K., Nakayama, H. and Tsujimoto, H. (2011) Comparison between immunohistochemistry and genetic clonality analysis for cellular lineage determination in feline lymphomas. J. Vet. Med. Sci. 73, 945-947.
Saulez, M.N., Schlipf, J.W., Cebra, C.K., McDonough, S.P. and Bird, K.E. (2004) Use of chemotherapy for treatment of a mixed-cell thoracic lymphoma in a horse. J. Am. Vet. Med. Assoc. 224, 733- 738.
Savage, C.J. (1998) Lymphoproliferative and myeloproliferative disorders. Vet. Clin. North Am. Equine Pract. 14, 563-578, vii.
Sellon, D.C. (2004) Disorders of the hematopoietic system. In: Equine Internal Medicine, 2nd edn., Ed: S.M. Reed, W. Bayly and D. Sellon, W.B. Saunders, St Louis, Missouri. pp 721-768.
Strauchen, J.A. (2004) Immunophenotypic and molecular studies in the diagnosis and classification of malignant lymphoma. Cancer Invest. 22, 138-148.
Taintor, J. and Schleis, S. (2011) Equine lymphoma. Equine Vet. Educ. 23, 205-213.
Tanimoto, T., Yamasaki, S. and Ohtsuki, Y. (1994) Primary splenic lymphoma in a horse. J. Vet. Med. Sci. 56, 767-769.
Thalheim, L., Williams, L.E., Borst, L.B., Fogle, J.E. and Suter, S.E. (2013) Lymphoma immunophenotype of dogs determined by immunohistochemistry, flow cytometry, and polymerase chain reaction for antigen receptor rearrangements. J. Vet. Intern. Med. 27, 1509-1516.
Weaver, M.P., Dobson, J.M. and Lane, J.G. (1996) Treatment of intranasal lymphoma in a horse by radiotherapy. Equine Vet. J. 28, 245-248.
Weiss, L.M. and Spagnolo, D.V. (1993) Assessment of clonality in lymphoid proliferations. Am. J. Pathol. 142, 1679-1682.
Wilkerson, M.J., Dolce, K., Koopman, T., Shuman, W., Chun, R., Garrett, L., Barber, L. and Avery, A. (2005) Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules. Vet. Immunol. Immunopathol. 106, 179-196.
during the embryogenic stage of pregnancy at doses manyfold greater than the recommended equine dose caused fetal anomalies, specifically masculinization of the female genitalia.
Each mL of Regu-Mate® (altrenogest) Solution 0.22% contains 2.2 mg of altrenogest in an oil solution.
ACTIONS: Regu-Mate® (altrenogest) Solution 0.22% produces a progestational effect in mares.
INDICATIONS: Regu-Mate® (altrenogest) Solution 0.22% is indicated to suppress estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season.
CONTRAINDICATIONS: Regu-Mate® (altrenogest) Solution 0.22% is contraindicated for use in mares having a previous or current history of uterine inflammation (i.e., acute, subacute, or chronic endometritis). Natural or synthetic gestagen therapy may exacerbate existing low-grade or “smoldering” uterine inflammation into a fulminating uterine infection in some instances. PRECAUTIONS: Various synthetic progestins, including altrenogest, when administered to rats
DOSAGE AND ADMINISTRATION: While wearing protective gloves, remove shipping cap and seal; replace with enclosed plastic dispensing cap. Remove cover from bottle dispensing tip and connect luer lock syringe (without needle). Draw out appropriate volume of Regu-Mate solution. (Note: Do not remove syringe while bottle is inverted as spillage may result.) Detach syringe and administer solution orally at the rate of 1 mL per 110 pounds body weight (0.044 mg/kg) once daily for 15 consecutive days. Administer solution directly on the base of the mare’s tongue or on the mare’s usual grain ration. Replace cover on bottle dispensing tip to prevent leakage. Excessive use of a syringe may cause the syringe to stick; therefore, replace syringe as necessary.
WHICH MARES WILL RESPOND TO REGU-MATE® (altrenogest) SOLUTION 0.22%: Extensive clinical trials have demonstrated that estrus will be suppressed in approximately 95% of the mares within three days; however, the post- treatment response depended on the level of ovarian activity when treatment was initiated. Estrus in mares exhibiting regular estrus cycles during the breeding season will be suppressed during treatment; these mares return to estrus four to five days following treatment and continue to cycle normally. Mares in winter anestrus with small follicles continued in anestrus and failed to exhibit normal estrus following withdrawal.
March and April). In addition, a high proportion of these mares responded with regular estrus cycles post-treatment.
SPECIFIC USES FOR REGU-MATE® (altrenogest) SOLUTION 0.22%: SUPPRESSION OF ESTRUS TO: 1. Facilitate attainment of regular cycles during the transition period from winter anestrus to the physiological breeding season. To facilitate attainment of regular cycles during the transition phase, mares should be examined to determine the degree of ovarian activity. Estrus in mares with inactive ovaries (no follicles greater than 20 mm in diameter) will be suppressed but these mares may not begin regular cycles following treatment. However, mares with active ovaries (follicles greater than 20 mm in diameter) frequently respond with regular post-treatment estrus cycles.
DOSAGE CHART:
Approximate Weight in Pounds
770 880 990
1100 1210 1320
Response in mares in the transition phase between winter anestrus and the summer breeding season depended on the degree of follicular activity. Mares with inactive ovaries and small follicles failed to respond with normal cycles post-treatment, whereas a higher proportion of mares with ovarian follicles 20 mm or greater in diameter exhibited normal estrus cycles post-treatment. Regu-Mate® (altrenogest) Solution 0.22% was very effective for suppressing the prolonged estrus behavior frequently observed in mares during the transition period (February,
Dose in mL
7 8 9
10 11 12
2. Facilitate management of the mare exhibiting prolonged estrus during the transition period. Estrus will be suppressed in mares exhibiting prolonged behavioral estrus either early or late during the transition period. Again, the posttreatment response depends on the level of ovarian activity. The mares with greater ovarian activity initiate regular cycles and conceive sooner than the inactive mares. Regu-Mate® (altrenogest) Solution 0.22% may be administered early in the transition period to suppress estrus in mares with inactive ovaries to aid in the management of these mares or to mares later in the transition
3. Permit scheduled breeding of mares during the physiological breeding season. To permit scheduled breeding, mares which are regularly cycling or which have active ovarian function should be given Regu-Mate® (altrenogest) Solution 0.22% daily for 15 consecutive days beginning 20 days before the date of the planned estrus. Ovulation will occur 5 to 7 days following the onset of estrus as expected for nontreated mares. Breeding should follow usual procedures for mares in estrus. Mares may be regulated and scheduled either individually or in groups.
ADDITIONAL INFORMATION: A 3-year well controlled reproductive safety study was conducted in 27 pregnant mares, and compared with 24 untreated control mares. Treated mares received 2 mL Regu-Mate® (altrenogest) Solution 0.22% /110 lb body weight (2x dosage recommended for estrus suppression) from day 20 to day 325 of gestation. This study provided the following data: 1. In filly offspring (all ages) of treated mares, clitoral size was increased. 2. Filly offspring from treated mares had shorter interval from Feb. 1 to first ovulation than fillies from their untreated mare counterparts.
3. There were no significant differences in reproductive performance between treated and untreated animals (mares & their respective offspring) measuring the following parameters: •
•
interval from Feb. 1 to first ovulation, in mares only.
• follicle size, mares only. •
• •
mean interovulatory interval from first to second cycle and second to third cycle, mares only.
at 50 days gestation, pregnancy rate in treated mares was 81.8% (9/11) and untreated mares was 100% (4/4).
period with active ovaries to prepare and schedule the mare for breeding.
•
•
stallion offspring from treated and control mares showed no differences in seminal volume, spermatozoal concentration, spermatozoal motility, and total sperm per ejaculate.
• testicular characteristics (scrotal width, testis weight, parenchymal weight, epididymal weight and height, testicular height, width & length) were the same between stallion offspring of treated and control mares.
stallion offspring from treated and control mares showed no difference in sexual behavior.
Solution 0.22% is readily absorbed by the skin. Skin contact must be avoided; protective gloves must be worn when handling this product.
REFERENCES: Shoemaker, C.F., E.L. Squires, and R.K. Shideler.
1989.Safety of Altrenogest in Pregnant Mares and on Health and Development of Offspring. Eq. Vet. Sci. (9); No. 2: 69-72. Squires, E.L., R.K. Shideler, and A.O. McKinnon.
1989.Reproductive Performance of Offspring from Mares Administered Altrenogest During Gestation. Eq. Vet. Sci. (9); No. 2: 73-76.
WARNING: Do not use in horses intended for food.
after 3 cycles, 11/12 treated mares were pregnant (91.7%) and 4/4 untreated mares were pregnant (100%).
HUMAN WARNINGS: Skin contact must be avoided as Regu-Mate® (altrenogest) Solution 0.22% is readily absorbed through unbroken skin. Protective gloves must be worn by all persons handling this product. Pregnant women or women who suspect they are pregnant should not handle Regu-Mate® (altrenogest) Solution 0.22%. Women of child bearing age should exercise extreme caution when handling this product. Accidental absorption could lead to a disruption of the menstrual cycle or prolongation of pregnancy. Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.
colt offspring of treated and control mares reached puberty at approximately the same age (82 & 84 weeks respectively).
INFORMATION FOR HANDLERS: WARNING: Regu-Mate® (altrenogest)
Effects of Overexposure: There has been no human use of this specific product. The information contained in this section is extrapolated from data available on other products of the same pharmacological class that have been used in humans. Effects anticipated are due to the progestational activity of altrenogest. Acute effects after a single exposure are possible; however, continued daily exposure has the potential for more untoward effects such as disruption of the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, prolongation of pregnancy and headaches. The oil base may also cause complications if swallowed. In addition, the list of people who should not handle this product (see below) is based upon the known effects of progestins used in humans on a chronic basis.
PEOPLE WHO SHOULD NOT HANDLE THIS PRODUCT. 1. Women who are or suspect they are pregnant. 2. Anyone with thrombophlebitis or thromboembolic disorders or with a history of these events.
3. Anyone with cerebral-vascular or coronary artery disease.
4. Women with known or suspected carcinoma of the breast.
5. People with known or suspected estrogen- dependent neoplasia.
6. Women with undiagnosed vaginal bleeding. 7. People with benign or malignant tumors which developed during the use of oral contraceptives or other estrogen-containing products. 8. Anyone with liver dysfunction or disease.
ACCIDENTAL EXPOSURE: Altrenogest is readily absorbed from contact with the skin. In addition, this oil based product can penetrate porous gloves. Altrenogest should not penetrate intact rubber or impervious gloves; however, if there is leakage
(i.e., pinhole, spillage, etc.), the contaminated area covered by such occlusive materials may have increased absorption. The following measures are recommended in case of accidental exposure. Skin Exposure: Wash immediately with soap and water. Eye Exposure: Immediately flush with plenty of water for 15 minutes. Get medical attention. If Swallowed: Do not induce vomiting. Regu- Mate® (altrenogest) Solution 0.22% contains an oil. Call a physician. Vomiting should be supervised by a physician because of possible pulmonary damage via aspiration of the oil base. If possible, bring the container and labeling to the physician.
CAUTION: For oral use in horses only. Keep this and all medication out of the reach of children.
Store at or below 25°C (77°F). NADA# 131-310, Approved by FDA. HOW SUPPLIED:
Regu-Mate® (altrenogest) Solution 0.22% (2.2 mg/mL).
Each mL contains 2.2 mg altrenogest in an oil solution.
Available in 1000 mL plastic bottles. * US Patents 3,453,267; 3,478,067; 3,484,462
Manufactured by: DPT Laboratories, San Antonio, TX 78215
Distributed by: Intervet Inc., Millsboro, DE 19966
© 2017 EVJ Ltd
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
